retatrutide clinical trial results 2024 2025 press release 📊 New late-stage show an investigational Lilly medicine reduced moderate-to-severe obstructive sleep apnea severity by an average 61 percent in adults living with obesity and OSA on the 9 🚨 Big retatrutide news dropped

The drug was first approved in 2010, but the problem was that a patient had to inject it daily

10.1038/nature07006 Nature 112 ScarpullaR

While injectable GLP-1 medications demonstrate significant weight loss of 10-20% through FDA-approved formulations, patches have no substantial evidence supporting their effectiveness

Compared with the control group, there was no significant difference in body weight change (%) among the groups that were administered different natural products (Fig

Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients